title: [Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
abstract: The clinical efficacy and safety of weekly paclitaxel therapy were studied retrospectively in 17 patients with advanced and recurrent gastric cancer who had previously been treated with TS-1 therapy. The overall response rate was 0%, but MST was 495 days. The adverse effects observed were grade 3 leukopenia in 2 patients (11.8%) and grade 1 and 2 alopecia in 13 patients (76.5%). However, weekly paclitaxel therapy was performed for all outpatients. Weekly paclitaxel therapy could be useful and safe as second-line chemotherapy.
authors.affiliation: Gastroenterological Center, Medical Center, Yokohama City University.
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Hatori
authors.forename: Chikara
authors.initials: C
authors.lastname: Kunisaki
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Ono
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Otsuka
authors.forename: Roppei
authors.initials: R
authors.lastname: Yamada
authors.forename: Takashi
authors.initials: T
authors.lastname: Ohshima
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Rino
authors.forename: Toshio
authors.initials: T
authors.lastname: Imada
mesh_terms: D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel